🚀 VC round data is live in beta, check it out!
Zevra Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zevra Therapeutics and similar public comparables like Prothena Corp., Upstream Bio, Rigel Pharmaceuticals, Luzhu Biotech and more.
Zevra Therapeutics Overview
About Zevra Therapeutics
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Founded
2006
HQ
Employees
59
Website
Sectors
Financials (LTM)
EV
$441M
Zevra Therapeutics Financials
Zevra Therapeutics reported last 12-month revenue of $117M and negative EBITDA of ($34M).
In the same LTM period, Zevra Therapeutics generated $95M in gross profit, ($34M) in EBITDA losses, and $68M in net income.
Revenue (LTM)
Zevra Therapeutics P&L
In the most recent fiscal year, Zevra Therapeutics reported revenue of $106M and EBITDA of $99M.
Zevra Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $117M | XXX | $106M | XXX | XXX | XXX |
| Gross Profit | $95M | XXX | $90M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | ($34M) | XXX | $99M | XXX | XXX | XXX |
| EBITDA Margin | (29%) | XXX | 93% | XXX | XXX | XXX |
| EBIT Margin | (31%) | XXX | (4%) | XXX | XXX | XXX |
| Net Profit | $68M | XXX | $83M | XXX | XXX | XXX |
| Net Margin | 59% | XXX | 78% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zevra Therapeutics Stock Performance
Zevra Therapeutics has current market cap of $569M, and enterprise value of $441M.
Market Cap Evolution
Zevra Therapeutics' stock price is $9.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $441M | $569M | 1.0% | XXX | XXX | XXX | $1.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZevra Therapeutics Valuation Multiples
Zevra Therapeutics trades at 3.8x EV/Revenue multiple, and (12.9x) EV/EBITDA.
EV / Revenue (LTM)
Zevra Therapeutics Financial Valuation Multiples
As of April 11, 2026, Zevra Therapeutics has market cap of $569M and EV of $441M.
Equity research analysts estimate Zevra Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zevra Therapeutics has a P/E ratio of 8.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $569M | XXX | $569M | XXX | XXX | XXX |
| EV (current) | $441M | XXX | $441M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | (12.9x) | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBIT | (12.4x) | XXX | (104.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | 4.9x | XXX | XXX | XXX |
| P/E | 8.3x | XXX | 6.8x | XXX | XXX | XXX |
| EV/FCF | 27.9x | XXX | (181.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zevra Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zevra Therapeutics Margins & Growth Rates
Zevra Therapeutics' revenue in the last 12 month grew by 41%.
Zevra Therapeutics' revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $1.6M for the same period.
Zevra Therapeutics' rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zevra Therapeutics' rule of X is 108% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Zevra Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | (29%) | XXX | 93% | XXX | XXX | XXX |
| EBITDA Growth | (222%) | XXX | (68%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 56% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 108% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 67% | XXX | 73% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 88% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zevra Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prothena Corp. | XXX | XXX | XXX | XXX | XXX | XXX |
| Upstream Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Rigel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Luzhu Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyverna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zevra Therapeutics M&A Activity
Zevra Therapeutics acquired XXX companies to date.
Last acquisition by Zevra Therapeutics was on XXXXXXXX, XXXXX. Zevra Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zevra Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZevra Therapeutics Investment Activity
Zevra Therapeutics invested in XXX companies to date.
Zevra Therapeutics made its latest investment on XXXXXXXX, XXXXX. Zevra Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zevra Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zevra Therapeutics
| When was Zevra Therapeutics founded? | Zevra Therapeutics was founded in 2006. |
| Where is Zevra Therapeutics headquartered? | Zevra Therapeutics is headquartered in United States. |
| How many employees does Zevra Therapeutics have? | As of today, Zevra Therapeutics has over 59 employees. |
| Who is the CEO of Zevra Therapeutics? | Zevra Therapeutics' CEO is Neil F. McFarlane. |
| Is Zevra Therapeutics publicly listed? | Yes, Zevra Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Zevra Therapeutics? | Zevra Therapeutics trades under ZVRA ticker. |
| When did Zevra Therapeutics go public? | Zevra Therapeutics went public in 2015. |
| Who are competitors of Zevra Therapeutics? | Zevra Therapeutics main competitors are Prothena Corp., Upstream Bio, Rigel Pharmaceuticals, Luzhu Biotech. |
| What is the current market cap of Zevra Therapeutics? | Zevra Therapeutics' current market cap is $569M. |
| What is the current revenue of Zevra Therapeutics? | Zevra Therapeutics' last 12 months revenue is $117M. |
| What is the current revenue growth of Zevra Therapeutics? | Zevra Therapeutics revenue growth (NTM/LTM) is 41%. |
| What is the current EV/Revenue multiple of Zevra Therapeutics? | Current revenue multiple of Zevra Therapeutics is 3.8x. |
| Is Zevra Therapeutics profitable? | No, Zevra Therapeutics is not profitable. |
| What is the current EBITDA of Zevra Therapeutics? | Zevra Therapeutics has negative EBITDA and is not profitable. |
| What is Zevra Therapeutics' EBITDA margin? | Zevra Therapeutics' last 12 months EBITDA margin is (29%). |
| What is the current EV/EBITDA multiple of Zevra Therapeutics? | Current EBITDA multiple of Zevra Therapeutics is (12.9x). |
| What is the current FCF of Zevra Therapeutics? | Zevra Therapeutics' last 12 months FCF is $16M. |
| What is Zevra Therapeutics' FCF margin? | Zevra Therapeutics' last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Zevra Therapeutics? | Current FCF multiple of Zevra Therapeutics is 27.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.